Stakeholders around the world can benefit from RWD as it can improve patient outcomes and speed at which products come to market.
Chitra Lele, PhD
Advertisement
Dr. Chitra Lele is Chief Scientific Officer, Sciformix Corporation.
Articles by Chitra Lele, PhD
The need for proactive pharmacovigilance is being increasingly acknowledged by all companies, regardless of their size and product mix, writes Dr. Chitra Lele.
Advertisement
Latest Updated Articles
The Power of Proactive PharmacovigilanceApril 21st 2015
The Growing Importance of Real World DataFebruary 18th 2017
Advertisement
Advertisement
Trending on PharmExec
1
Bayer Shares Briefly Dip After Activist Investor Offloads Millions of Dollars in Company Stock
2
Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio
3
Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science
4
FDA Sends Warning Letter to ImmunityBio for Misleading Claims in Advertisement
5